Parry MG, et al. - For the treatment of men with high-risk prostate cancer, researchers compared intensity-modulated radiation therapy (IMRT) to the prostate and the pelvic lymph nodes vs prostate-only IMRT in terms of treatment-related toxicity. They used data from the Cancer Registry, the National Radiotherapy Dataset, and Hospital Episode Statistics, to find patients who received IMRT for high-risk localized or locally advanced prostate cancer between 2010 and 2013. No increased GI or genitourinary toxicity was evident at 3 years in relation to the inclusion of pelvic lymph nodes in radiation fields for high-risk or locally advanced prostate cancer.